Advances in our understanding of pancreatic ductal adenocarcinoma (PDAC) and its tumor microenvironment (TME) have the potential to transform treatment for the hundreds of thousands of patients who are diagnosed each year. Whereas the clinical assessment of cancer cell genetics has grown increasingly sophisticated and personalized, current protocols to evaluate the TME have lagged, despite evidence that the TME can be heterogeneous within and between patients. Here, we outline current protocols for PDAC diagnosis and management, review novel biomarkers, and highlight potential opportunities and challenges when evaluating the PDAC TME as we prepare to translate emerging TME-directed therapies to the clinic.
对胰腺导管腺癌（PDAC）及其肿瘤微环境（TME）认识的深入，有望为每年数十万新确诊患者带来治疗模式的革新。尽管肿瘤细胞遗传学的临床评估已日趋精细化和个体化，但当前针对TME的评估方案却相对滞后，尽管有证据表明TME在患者内部及患者间均存在异质性。本文系统梳理了当前PDAC诊断与管理的临床路径，评述了新型生物标志物的进展，并重点探讨了在推动新兴TME靶向疗法向临床转化过程中，评估PDAC肿瘤微环境所面临的机遇与挑战。
Clinical Evaluation of the Pancreatic Cancer Microenvironment: Opportunities and Challenges
肿瘤(癌症)患者之家